Nuclear factor-κB is constitutively active in C-cell carcinoma and required for RET-induced transformation

Cancer Research

Volumn 61, Issue 11, 2001, Pages 4526-4535

  Ludwig, Leopold ^a   Kessler, Heidi ^a   Wagner, Martin ^a   Hoang Vu, Cuong ^b   Dralle, Henning ^b   Adler, Guido ^a   Böhm, Bernhard O ^a   Schmid, Roland M ^a  

^a UNIVERSITY OF ULM   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CHUK PROTEIN, HUMAN; CHUK PROTEIN, MOUSE; DNA; DNA BINDING PROTEIN; DROSOPHILA PROTEIN; DRUG DERIVATIVE; I KAPPA B; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; IKBKB PROTEIN, MOUSE; IKBKE PROTEIN, HUMAN; IKBKE PROTEIN, MOUSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN; MITOGEN ACTIVATED PROTEIN KINASE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; ONCOPROTEIN; PROTEIN RET; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RAS PROTEIN; RET ONCOGENE PROTEIN, DROSOPHILA; RET PROTEIN, MOUSE; TRANSCRIPTION FACTOR RELA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAF PROTEIN;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL NUCLEUS; CELL STRAIN 3T3; CELL TRANSFORMATION; CYTOLOGY; DIMERIZATION; DRUG ANTAGONISM; FIBROBLAST; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MEDULLARY CARCINOMA; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; THYROID TUMOR; CARCINOGENESIS; CELL DEATH; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HELA CELL; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTO ONCOGENE; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL;

3T3 CELLS; ACETYLCYSTEINE; ANIMALS; APOPTOSIS; CARCINOMA, MEDULLARY; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; DIMERIZATION; DNA, NEOPLASM; DNA-BINDING PROTEINS; DROSOPHILA PROTEINS; FIBROBLASTS; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0035354187     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant, and adult rat tissues
2. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas
3. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome
4. Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells
5. Mutations of the RET proto-oncogene in Hirschsprung's disease
6. RET oncogene
7. Renal and neuronal abnormalities in mice lacking GDNF
8. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret
9. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
10. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
11. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations
12. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
13. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas
14. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis
15. Signaling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): Evidence for a divergence of the ERKs and JNKs pathways induced by Ret
16. Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells
17. Rel/NF-κB/IκB proteins and cancer
18. Rel/NF-κB and IκB factors in oncogenesis
19. Signal transduction through NF-κB
20. Bridging the gap: Composition, regulation, and physiological function of the IκB kinase complex
21. Control of IκBα proteolysis by site-specific, signal-induced phosphorylation
22. Differential regulation of IκB kinase α and β by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1
23. IκB kinase-β. NF-κB activation and complex formation with IκB kinase-α and NIK
24. NAK is an IκB kinase-activating kinase
25. Coordinate regulation of IκB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-κB-inducing kinase
26. Activation of the IκBα kinase complex by MEKK1, a kinase of the JNK pathway
27. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation
28. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB
29. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation
30. Oncogenic Ras enhances NF-κB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways
31. NF-κB is a target of AKT in anti-apoptotic PDGF signaling
32. Oncogene activation in human myeloid leukemia
33. Sulfasalazine: A potent and specific inhibitor of nuclear factor κB
34. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation
35. Plasma membrane-targeted Raf kinase activates NF-κB and human immunodeficiency virus type 1 replication in T lymphocytes
36. Activation of MAP kinase kinase is necessary and sufficient for PCI2 differentiation and for transformation of NIH 3T3 cells
37. Transcriptional regulation of NF-κB2: Evidence for κ B-mediated positive and negative autoregulation
38. Structural and functional analysis of NF-κB. Determinants of DNA binding specificity and protein interaction
39. CD97: A dedifferentiation marker in human thyroid carcinomas
40. Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation
41. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line
42. Human medullary thyroid carcinoma in culture provides a model relating growth dynamics, endocrine cell differentiation, and tumor progression
43. An essential role for NF-κB in preventing TNF-α-induced cell death
44. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras
45. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines
46. Overexpression of RelA in transgenic mouse thymocytes: Specific increase in levels of the inhibitor protein IκBα
47. Defective IκBα in Hodgkin cell lines with constitutively active NF-κB
48. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells
49. HTLV-I Tax protein binds to MEKK1 to stimulate IκB kinase activity and NF-κB activation
50. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase
51. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor
52. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-κB p65 transactivation mediated by tumor necrosis factor
53. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor
54. 1to-S-phase transition
55. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1